Triple-Negative Breast Cancer

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit.

Pembrolizumab plus chemotherapy as adjuvant/neoadjuvant therapy demonstrated positive even-free survival outcomes in the KEYNOTE-522 study for patients with triple-negative breast cancer.

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients.

Black women with triple-negative breast cancer may have worse survival outcomes compared with White women, even after adjusting for external factors.

Pembrolizumab plus chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy in patients with early triple-negative breast cancer was superior in terms of event-free survival versus matched placebo.

The TROP2-directed antibody-drug conjugate datopotamab deruxtecan induced responses and an acceptable safety profile in a cohort of patients with triple-negative breast cancer treated on a phase 1 trial.

The FDA’s Oncologic Drugs Advisory Committee voted 7 to 2 in favor of atezolizumab plus nab-paclitaxel maintaining its accelerated approval to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of waiting for additional event-free survival data to become available before making a regulatory decision regarding a biologics license application for pembrolizumab in early triple-negative breast cancer.

Adam Brufsky, MD, PhD, presented data investigating immunotherapeutic options in the neoadjuvant setting for patients with triple-negative breast cancer.

The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.

Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year resulted in significantly improved disease-free survival rates compared with observation.

Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.

Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.

Frontline pembrolizumab (Keytruda) plus chemotherapy for patients with advanced triple-negative breast cancer showed efficacy across key subgroups, including patients with PD-L1 expression by combined positive score.

Treatment with ipatasertib plus paclitaxel (Abraxane) failed to show a significant improvement in progression-free survival versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable, or metastatic triple-negative breast cancer.

Final data from a phase 2 trial suggested that the administration of trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

The FDA approved the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer who may be appropriate for treatment with pembrolizumab (Keytruda).

Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.

“PD-L1 expression was significantly associated with pCR, which increased with higher PD-L1 expression on immune cells,” said Giampaolo Bianchini, an author of the NeoTRIPaPDL1 study.

Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.

The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in patients with brain metastasis-negative, metastatic triple-negative breast cancer met its primary end point of progression-free survival.

The combination demonstrated a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of individuals with early triple-negative breast cancer, regardless of PD-L1 expression.

For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.

A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.

Nab-paclitaxel/carboplatin should be considered a first-line option in the setting of triple-negative breast cancer.

Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy.